Demand for Hepatitis E Diagnostic Tests in USA

Demand for Hepatitis E Diagnostic Tests in USA 2025 to 2035

Demand for hepatitis E diagnostic tests in the USA is projected to grow from USD 14.20 million in 2025 to approximately USD 21.80 million by 2035, recording an absolute increase of USD 7.60 million over the forecast period. This translates into a total growth of 53.52%, with demand forecast to expand at a compound annual growth rate (CAGR) of 4.80% between 2025 and 2035.

Quick Stats for USA Hepatitis E Diagnostic Tests Industry

• USA Hepatitis E Diagnostic Tests Sales Value (2025): USD 14.20 million
• USA Hepatitis E Diagnostic Tests Forecast Value (2035): USD 21.80 million
• USA Hepatitis E Diagnostic Tests Forecast CAGR: 4.80%
• Leading Test Type in USA Hepatitis E Diagnostic Tests Industry: ELISA HEV IgM Tests (48.30%)
• Key Growth Regions in USA Hepatitis E Diagnostic Tests Industry: West, Northeast, South, Midwest
• Regional Leadership: West holds the leading position in demand
• Key Players in USA Hepatitis E Diagnostic Tests Industry: F. Hoffmann-La Roche Limited, Wantai BioPharm, PerkinElmer Incorporated, Altona Diagnostics, MP Biomedicals LLP, Dia.Pro Diagnostic Bioprobes srl, ELITechGroup, Primerdesign Limited, Mikrogen GmbH, Fortress Diagnostics

The overall demand size is expected to grow by more than 1.5 times during the same period, supported by increasing awareness of waterborne hepatitis E transmission and rising adoption of comprehensive screening protocols, growing utilization of blood safety monitoring technologies, expanding laboratory diagnostic capabilities, and comprehensive infectious disease surveillance requirements throughout the USA.

The ELISA HEV IgM tests segment is projected to account for 48.30% of hepatitis E diagnostic tests demand in 2025. ELISA HEV IgM applications are widely used in the USA for hospital laboratories, blood screening facilities, and diagnostic testing centers where high-sensitivity acute infection detection profiles, antibody-level discrimination characteristics, and comprehensive serological characterization benefits remain essential for infectious disease monitoring applications and patient safety optimization.

The hospitals segment is expected to represent 41.20% of hepatitis E diagnostic tests demand in 2025. Hospital applications are fundamental to the industry because they provide the clinical necessity, testing consistency, and workflow reliability required for high-volume diagnostic operations and patient care applications.

Between 2020 and 2025, hepatitis E diagnostic tests demand in the USA experienced steady expansion, driven by increasing recognition of hepatitis E prevalence and growing adoption of advanced serological diagnostics benefits for infection detection optimization and patient management enhancement. The sector developed as hospitals and clinical laboratories, especially in major medical centers, recognized the need for reliable diagnostic systems and effective screening solutions to achieve clinical objectives while meeting regulatory standards and patient safety requirements. Healthcare companies and diagnostic suppliers began emphasizing technology integration and testing acceptance to maintain competitive advantages and operational viability.

Between 2025 and 2030, demand for hepatitis E diagnostic tests in the USA is projected to expand from USD 14.20 million to USD 18.00 million, resulting in a value increase of USD 3.80 million, which represents 50.0% of the total forecast growth for the decade. This phase of growth will be shaped by accelerating molecular diagnostic adoption campaigns, rising laboratory automation investment, and growing compliance requirements for advanced infectious disease monitoring systems across USA regions, particularly in areas where hospital infrastructure and precision medicine initiatives are accelerating hepatitis E diagnostics adoption. Increasing integration of automated immunoassay technology in diagnostic systems and growing adoption of point-of-care testing platforms continue to drive demand.

Healthcare authorities and diagnostic companies are expanding their technology capabilities to address the growing complexity of modern infectious disease requirements and screening standards, with USA operations leading investments in molecular diagnostic enhancement methods and efficient patient monitoring optimization systems.

From 2030 to 2035, demand is forecast to grow from USD 18.00 million to USD 21.80 million, adding another USD 3.80 million, which constitutes 50.0% of the overall ten-year expansion. This period is expected to be characterized by expansion of advanced molecular testing applications, development of enhanced automated diagnostic capabilities, and implementation of comprehensive hepatitis E diagnostic technology programs across different clinical and laboratory sectors. The growing adoption of precision diagnostics systems and enhanced screening optimization platforms, particularly in major hospital centers and reference laboratory operations, will drive demand for more sophisticated diagnostic solutions and validated immunoassay systems.

USA Hepatitis E Diagnostic Tests Industry Key Takeaways

Metric	Value
USA Hepatitis E Diagnostic Tests Sales Value (2025)	USD 14.20 million
USA Hepatitis E Diagnostic Tests Forecast Value (2035)	USD 21.80 million
USA Hepatitis E Diagnostic Tests Forecast CAGR (2025-2035)	4.80%

Why is the USA Hepatitis E Diagnostic Tests Industry Growing?

The USA hepatitis E diagnostic tests industry is driven by a surge in the broader infectious disease surveillance sector. A considerable growth in demand for both advanced diagnostic solutions and immunological screening equipment has created a larger base of hospitals, clinical processors, and laboratory professionals requiring reliable hepatitis E diagnostic products. Moreover, changing regulatory patterns mandate the use of efficient molecular systems for optimal infection detection performance and patient safety optimization. This compliance-driven demand establishes a consistent, regulation-based foundation. As new operators enter the healthcare infrastructure segment and existing clinical practices are modernized, the need for standard-issue and specialized hepatitis E diagnostic products forms a stable foundation for the industry's growth, ensuring a continuous stream of customers driven by regulatory necessity and clinical compliance.

Technological innovation serves as a powerful secondary engine for this growth. Modern hepatitis E diagnostic systems are no longer just basic screening equipment; they are advanced immunoassay products. The rapid adoption of specialized ELISA technologies has become a major selling point, significantly reducing testing complexity and enhancing operational reliability. Beyond traditional options, manufacturers are integrating advanced molecular diagnostic systems for seamless incorporation with digitally conscious monitoring approaches, and compatibility with various clinical requirements. These features, coupled with improvements in sensitivity efficiency, system convenience, and equipment quality, are compelling both hospital and laboratory operators to upgrade from basic assays, driving a cycle of replacement and premiumization within the industry.

An increasing emphasis on diagnostic efficiency, particularly exploration of advanced immunoassay technologies, is pushing demand for higher-quality, more diverse hepatitis E diagnostic varieties. The segment has also expanded beyond traditional clinical channels, with growing interest from the blood banking sector, pharmaceutical applications, and even specialty monitoring units. This diversification, combined with the rise of specialized platforms that improve accessibility for all operators, ensures that manufacturers can reach a wider audience than ever before. This confluence of efficiency, innovation, and accessibility creates a fertile ground for continued industry expansion.

Segmental Analysis

The industry is segmented by test type, end use, and region. By test type, the industry is divided into ELISA HEV IgM tests, ELISA HEV IgG tests, rapid diagnostic tests, PCR tests, and others. In terms of end use, the industry is segmented into hospitals, diagnostics laboratories, blood banks, and others, with ELISA HEV IgM tests representing a key growth and innovation hub for diagnostic technologies. Regionally, the industry is divided into West, Northeast, South, and Midwest.

Why Do ELISA HEV IgM Tests Account for High Share of 48.30%?

The ELISA HEV IgM tests segment is projected to account for 48.30% of hepatitis E diagnostic tests demand in 2025, making it the leading test type across the sector. This dominance reflects the diagnostic requirements and operational acceptance needs of screening systems for existing hospital centers and laboratory applications where acute infection detection is optimized through proven reliability characteristics and integrated design architecture.

In the USA, where substantial healthcare infrastructure requires diagnostic integration without complete system redesign, ELISA HEV IgM hepatitis E diagnostic solutions provide practical pathways for screening enhancement while maintaining operational preferences. Continuous innovations are improving sensitivity optimization, reliability preservation, and versatility parameters, enabling hospital operators to achieve high performance standards while maximizing operational satisfaction.

• High-sensitivity detection and existing system integration make ELISA HEV IgM tests the preferred test type for enhancing hospital centers and laboratory operations.
• Reliability demonstration and performance track records are enhancing operator confidence and equipment viability across large-scale adoption initiatives.

Why Do Hospitals Hold High Share of 41.20%?

Hospitals are expected to represent 41.20% of hepatitis E diagnostic tests demand in 2025, reflecting the critical role of clinical testing requiring comprehensive operational solutions. Hospital operations including diagnostic projects, laboratory facilities, and patient care systems generate consistent demand for hepatitis E diagnostics that support efficient operational utilization and performance optimization.

Hepatitis E diagnostic systems are widely adopted for hospital facilities due to significant testing efficiency benefits and enhanced operational capabilities. Their reliable, high-performance operation provides effective, cost-efficient diagnostic solutions, enhancing operational independence for clinical users.

• Clinical requirements and hospital operations drive substantial demand for specialized hepatitis E diagnostics designed for clinical applications.
• Operational optimization and performance efficiency demands create consistent diagnostic requirements across major clinical regions and hospital facilities.

What are the Drivers, Restraints, and Key Trends in the USA Hepatitis E Diagnostic Tests Industry?

The demand for hepatitis E diagnostic tests in the USA is advancing steadily due to increasing regulatory requirements and growing recognition of advanced immunoassay necessity for infection detection, with the West region serving as a key driver of innovation and healthcare modernization. The sector faces challenges including initial cost considerations, technology limitations with certain applications, and ongoing concerns regarding complexity constraints and specialized expertise requirements.

Growth in Hospital Infrastructure Development and Infectious Disease Programs

The enhancement of clinical standards, gaining particular significance through regulatory trends and infectious disease campaigns, is enabling hepatitis E diagnostic providers to achieve differentiation without prohibitive production costs, providing predictable demand patterns through compliance requirements and operator preferences. Enhanced clinical standards offering substantial opportunities for hepatitis E diagnostic systems and integrated applications provide foundational dynamics while allowing providers to secure hospital center agreements and distribution partnerships.

Incorporation of Advanced Molecular Testing Capabilities and High-Sensitivity Diagnostic Systems

Modern hepatitis E diagnostic providers and clinical operators are establishing advanced manufacturing networks and centralized production facilities that improve manufacturing efficiency through process standardization and reliability analytics. Integration of molecular testing enhancement systems, high-sensitivity immunoassay technology, and coordinated quality management enables more efficient production operations across multiple manufacturing regions.

Creation of Automated Testing Systems and Enhanced Screening Targeting Methods

The expansion of automated testing systems and screening segmentation is driving development of specialized hepatitis E diagnostic systems with enhanced immunoassay profiles, improved reliability characteristics, and optimized clinical attributes that address current limitations and expand diagnostic applications beyond traditional assays. These specialized systems require sophisticated monitoring capabilities and performance expertise that exceed traditional manufacturing requirements, creating specialized demand segments with differentiated equipment propositions. Producers are investing in screening targeting and clinical optimization to serve emerging hospital applications while supporting innovation in performance development and operator engagement.

Analysis of USA Hepatitis E Diagnostic Tests Industry by Key Region

Region	CAGR (2025-2035)
West	5.20%
Northeast	4.80%
South	4.60%
Midwest	4.40%

The USA hepatitis E diagnostic tests demand is witnessing steady growth, supported by rising compliance requirements, expanding hospital center initiatives, and the deployment of advanced diagnostic technologies across regions. West leads the nation with a 5.20% CAGR, reflecting a strong clinical base, substantial infectious disease surveillance development, and established molecular innovation facilities.

Why Does the West Region Dominate Hepatitis E Diagnostic Tests Demand?

Demand for hepatitis E diagnostic tests in West is projected to exhibit strong growth with a CAGR of 5.20% through 2035, driven by a strong clinical base, substantial infectious disease surveillance development creating advanced diagnostic opportunities, and a concentration of innovation advancement across California, Oregon, Washington, Nevada, and surrounding states.

Advanced molecular programs and clinical control initiatives are expanding hepatitis E diagnostic tests adoption among manufacturers, hospital centers, and laboratory suppliers pursuing compliance optimization, clinical development, and specialized processing projects throughout major urban hubs and medical corridors.

• Clinical base and infectious disease surveillance infrastructure capabilities are requiring comprehensive diagnostic strategies and screening solutions, driving demand for hepatitis E diagnostic systems with demonstrated clinical enhancement performance capabilities and permanent molecular assurance throughout diverse hospital operations.
• Infectious disease surveillance development and processing concentration are generating substantial hepatitis E diagnostic tests demand across clinical companies, manufacturers, and molecular suppliers serving laboratory applications and compliance requirements.

Why Does the Northeast Region Demonstrate Strong Growth?

Demand for hepatitis E diagnostic tests in Northeast is projected to grow with a CAGR of 4.80% through 2035, supported by established clinical presence, comprehensive infectious disease surveillance development, and strong manufacturing facilities across New York, Pennsylvania, Massachusetts, New Jersey, and surrounding states.

Established clinical presence and manufacturing leadership are supporting hepatitis E diagnostic tests adoption throughout manufacturer facilities, laboratory operations, and molecular distribution centers serving compliance enhancement and processing applications.

• Strong clinical ecosystem and manufacturing networks are enabling hepatitis E diagnostic tests integration across molecular producers, manufacturers, and diagnostic suppliers pursuing advanced compliance development and clinical programs.
• Premium infectious disease surveillance capabilities and clinical excellence are driving hepatitis E diagnostic tests demand among leading manufacturer corporations, molecular centers, and specialized clinical firms focused on performance enhancement, diagnostic optimization, and manufacturing development targeting compliance applications and advanced laboratory operations.

Why Does the South Region Show Consistent Demand?

Demand for hepatitis E diagnostic tests in South is forecast to advance with a CAGR of 4.60% through 2035, driven by expanding clinical capabilities, growing infectious disease surveillance investment, and increasing molecular consciousness across Texas, Florida, Georgia, North Carolina, and surrounding states.

Rising clinical sector development and manufacturing partnerships are supporting hepatitis E diagnostic tests integration across diagnostic producers, manufacturer facilities, and molecular distributors pursuing compliance enhancement, laboratory expansion, and clinical initiatives throughout expanding hospital regions and urban centers.

• Growing clinical infrastructure and infectious disease surveillance investment are creating opportunities for hepatitis E diagnostic tests adoption across emerging diagnostic hubs, manufacturer facilities, and molecular distribution centers in major metropolitan areas and clinical corridors.
• Laboratory expansion and molecular growth are driving hepatitis E diagnostic tests demand among clinical operators seeking enhanced performance capabilities and participation in advanced diagnostic programs.

Why Does the Midwest Region Depict Consistent Growth?

Demand for hepatitis E diagnostic tests in Midwest is expected to expand with a CAGR of 4.40% through 2035, supported by manufacturing capabilities, clinical infrastructure development, and growing manufacturer efficiency presence across Illinois, Ohio, Wisconsin, Michigan, and surrounding states.

Clinical expertise and production capabilities are driving hepatitis E diagnostic tests demand among laboratory producers, molecular suppliers, and manufacturing companies serving diagnostic production and clinical applications.

• Growing manufacturing development and clinical investment are supporting hepatitis E diagnostic tests adoption across emerging production hubs, laboratory facilities, and manufacturer centers pursuing performance enhancement and diagnostic programs.
• Expanding clinical infrastructure and manufacturing integration are creating opportunities for hepatitis E diagnostic tests utilization across molecular suppliers, laboratory production facilities, and manufacturer operations seeking clinical diagnostic production, molecular support, and manufacturing capabilities throughout major clinical regions and emerging manufacturer laboratory centers.

Competitive Landscape of USA Hepatitis E Diagnostic Tests Industry

USA hepatitis E diagnostic tests demand is defined by competition among established laboratory corporations, specialized diagnostic companies, and integrated molecular producers, with major manufacturer operators maintaining significant influence through production resources and manufacturing capabilities. Companies are investing in diagnostic advancement, screening optimization, molecular acceptance technologies, and comprehensive performance services to deliver effective, reliable, and efficient clinical solutions across USA hospital and manufacturer applications.

F. Hoffmann-La Roche Limited dominates with a 14.80% share, offering comprehensive immunoassay diagnostic solutions including advanced equipment, performance enhancement technologies, and distribution services with a focus on hospital applications, clinical consistency, and screening optimization across USA operations. The company continues investing in diagnostic programs, distribution strategies, and hepatitis E diagnostic innovation while expanding operational presence and advanced manufacturer applications.

Wantai BioPharm provides specialized ELISA solutions with emphasis on performance development and manufacturing excellence. PerkinElmer Incorporated focuses on premium molecular development and hospital applications. Altona Diagnostics emphasizes laboratory development and specialized manufacturer equipment production. MP Biomedicals LLP offers diagnostic technology solutions and professional performance support. Dia.Pro Diagnostic Bioprobes srl specializes in hospital screening development and distribution programs.

USA Hepatitis E Diagnostic Tests Industry - Stakeholder Contribution Framework

The USA hepatitis E diagnostic tests industry is a critical backbone for national clinical optimization, supporting hospital installations, manufacturer infrastructure, and laboratory applications. With a projected demand value driven by clinical development, laboratory equipment adoption cycles, and diagnostic technology advancement, the sector's resilience depends on collaborative engagement among government agencies, manufacturer operators, diagnostic companies, and investors to modernize infrastructure, enhance efficiency, and secure supply chains.

How Governments Could Accelerate Infrastructure Modernization and Industry Competitiveness?

• Federal Clinical Infrastructure Grants: Expand funding through the Department of Health and Human Services and Centers for Disease Control and Prevention for R&D into advanced diagnostic materials, efficiency-enhanced technologies, and monitoring systems to enhance performance and longevity.
• Tax Incentives for Equipment Installation: Offer investment tax credits for operators replacing conventional assays with high-efficiency hepatitis E diagnostics, molecular systems, or smart clinical systems that reduce maintenance consumption and operational costs.
• Domestic Manufacturing and Production Support: Implement policies and strategic reserves for domestic diagnostic production, ensuring a resilient supply of raw materials and mitigating import dependency and price volatility.
• Standardized Clinical and Certification Policies: Introduce unified federal standards for hepatitis E diagnostic manufacturing, performance testing, and installation inspection to streamline regulatory approval and boost interoperability.
• Permitting Process Reform: Expedite environmental reviews and permitting for critical diagnostic projects that enhance national clinical grid efficiency and hospital capacity.
• Digital Monitoring Mandates: Promote the deployment of smart sensors, wireless connectivity, and remote monitoring technologies as part of diagnostic management protocols.

How Industry Bodies & Associations Could Strengthen Sector Coordination and Technical Leadership?

• Unified Material and Clinical Standards: Develop consensus-based benchmarks for diagnostic grades, clinical ratings, and performance standards to ensure interoperability and system-wide efficiency.
• Workforce Development Programs: Create certification pathways for diagnostic technicians, clinical installers, and hospital engineers to address the skilled labor shortage and ensure quality installation.
• Collaborative R&D Consortia: Establish joint programs linking operators, manufacturers, and research institutions to drive innovation in molecular-detection technologies, advanced materials, and monitoring systems.
• Performance Data Repositories: Build centralized industry databases for performance incident data, efficiency rates, and material performance to inform better design and maintenance standards.
• Public Outreach and Awareness: Promote the role of modern diagnostic infrastructure in clinical reliability, economic growth, and laboratory protection through coordinated industry campaigns.

How Hepatitis E Diagnostic Tests Manufacturers & Technology Suppliers Could Capture Value and Drive Innovation?

• Advanced Diagnostic Manufacturing: Invest in production technologies for high-grade molecular systems, efficiency-enhanced containers, and smart clinical solutions for demanding applications.
• Clinical Monitoring System Integration: Develop integrated diagnostic platforms combining smart sensor data, wireless monitoring, and performance analytics for predictive maintenance.
• Supply Chain Digitalization: Implement digital traceability from component sourcing to final installation, using blockchain or QR codes to ensure material provenance and quality compliance.
• Partnership with Research Institutions: Collaborate with national labs on next-generation materials, such as advanced diagnostic technologies and composite clinical systems for high-performance applications.
• Hospital Optimization: Introduce automated manufacturing systems, advanced molecular applications, and modular container fabrication to lower manufacturing costs and improve throughput.

How Manufacturer Operators & Infrastructure Companies Could Optimize Hospital Efficiency and Demand Expansion?

• Digital Asset Integration: Create digital replicas of diagnostic assets integrated with real-time sensor data to optimize performance, predict maintenance, and simulate efficiency scenarios.
• Scale-up of High-Value Applications: Focus on diagnostic specifications for hospital developments, high-efficiency clinical projects, and laboratory transportation networks.
• Collaborative Supply Ecosystems: Develop long-term contracts with container manufacturers and technology suppliers to ensure consistent quality and secure capacity during expansion cycles.
• Pilot-to-Field Deployment Transition: Use phased testing for new diagnostic technologies, such as advanced molecular systems for manufacturer service, before full-scale field deployment.
• Lifecycle Cost Optimization: Invest in premium diagnostic materials and technologies during installation to reduce long-term maintenance and operational expenses.

How Hospital & Service Companies Could Lead Cross-Sector Integration?

• Manufacturer and Utility Integration: Deploy advanced monitoring and optimization technologies for aging distribution networks in urban and hospital areas.
• Facility and Asset Enhancement: Incorporate real-time clinical management platforms that combine performance data with efficiency assessment for a comprehensive view of asset health.
• Distribution and Grid System Management: Apply advanced efficiency-based methodologies to prioritize maintenance on vast and often complex diagnostic networks.
• Regional Testing and Validation Hubs: Create regional facilities to test and validate new monitoring tools, efficiency technologies, and diagnostic systems under simulated field conditions.
• Diagnostic Life Extension Initiatives: Reuse and upgrade container segments for enhanced efficiency services and optimize rehabilitation programs through advanced technology and smart management systems.

How Engineering & Construction Firms Could Unlock Application Innovation and Demand Access?

• Design and Material Expansion: Develop customized diagnostic solutions for challenging environments, including urban conditions, weather zones, and high-efficiency applications.
• Modular Clinical Applications: Integrate prefabricated and pre-optimized diagnostic systems into facility design to reduce field installation time and costs.
• Advanced Project Delivery Systems: Offer integrated EPC (Engineering, Procurement, and Construction) platforms that include digital as-built handover with all diagnostic material records.
• Design for Hospital Services: Partner with operators to provide co-engineered diagnostic systems optimized for constructability, operability, and long-term efficiency.
• Digital Platform Development: Launch project management platforms for standardized container components, procurement tracking, and quality assurance documentation.

How Investors and Financial Enablers Could Unlock Growth and Technology Scalability?

• Venture Capital for Technology Startups: Support early-stage companies developing novel monitoring systems, efficiency-based detection, and AI-driven clinical software.
• Infrastructure and Modernization Financing: Provide capital for diagnostic replacement programs, manufacturer facility upgrades, and digital control system installations.
• Public-Private Investment Platforms: Create co-financed funds for pilot projects demonstrating hospital efficiency or infrastructure transportation in enhanced or new-built diagnostic systems.
• Strategic Consolidation Funding: Back mergers and acquisitions that consolidate fragmented diagnostic technology, service, or manufacturing companies to achieve scale and geographic reach.
• Performance-Linked Financing Models: Tie loan terms and investor returns to key performance indicators like reduced clinical consumption, improved efficiency records, and enhanced hospital performance.
• Laboratory Transition Financing Programs: Channel innovation-oriented funds into diagnostic systems dedicated to hospital efficiency, laboratory development, and clinical efficiency networks.

Key Players in USA Hepatitis E Diagnostic Tests Industry

• F. Hoffmann-La Roche Limited
• Wantai BioPharm
• PerkinElmer Incorporated
• Altona Diagnostics
• MP Biomedicals LLP
• Dia.Pro Diagnostic Bioprobes srl
• ELITechGroup
• Primerdesign Limited
• Mikrogen GmbH
• Fortress Diagnostics

Scope of the Report

Item	Value
Quantitative Units	USD 21.80 million
Test Type	ELISA HEV IgM Tests, ELISA HEV IgG Tests, Rapid Diagnostic Tests, PCR Tests, Others
End Use	Hospitals, Diagnostics Laboratories, Blood Banks, Others
Regions Covered	West, Northeast, South, Midwest
Key Companies Profiled	F. Hoffmann-La Roche Limited, Wantai BioPharm, PerkinElmer Incorporated, Altona Diagnostics, MP Biomedicals LLP, Dia.Pro Diagnostic Bioprobes srl, ELITechGroup, Primerdesign Limited, Mikrogen GmbH, Fortress Diagnostics
Additional Attributes	Sales by test type and end use segment, regional demand trends across West, Northeast, South, and Midwest, competitive landscape with established laboratory corporations and diagnostic suppliers, manufacturer facility preferences for ELISA versus rapid testing equipment, integration with hospital centers and advanced diagnostic optimization policies particularly advanced in West region

USA Hepatitis E Diagnostic Tests Industry by Segments

• Test Type :

  • ELISA HEV IgM Tests
  • ELISA HEV IgG Tests
  • Rapid Diagnostic Tests
  • PCR Tests
  • Others

• End Use :

  • Hospitals
  • Diagnostics Laboratories
  • Blood Banks
  • Others

• Region :

  • West
  • Northeast
  • South
  • Midwest